MECHANISTIC KIDNEY MODELS FOR CREATININE: RELEVANCE OF OCT2 TRANSPORT DRIVING FORCE TO PREDICTION OF CREATININE-DRUG INTERACTIONS

被引：0
|
作者：
Scotcher, Daniel [1 ]
Arya, Vikram [2 ]
Yang, Xinning [2 ]
Zhao, Ping [3 ]
Zhang, Lei K. [2 ]
Huang, Shiew-Mei [2 ]
Rostami-Hodjegan, Amin [1 ]
Galetin, Aleksandra [1 ]
机构：
[1] Univ Manchester, Manchester M13 9PL, Lancs, England
[2] US FDA, Rockville, MD 20857 USA
[3] Bill & Melinda Gates Fdn, Seattle, WA USA
来源：
DRUG METABOLISM AND PHARMACOKINETICS | 2020年 / 35卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
A12
引用
收藏
页码：S22 / S22
页数：1
相关论文
共 11 条
  • [1] Mechanistic Models as Framework for Understanding Biomarker Disposition: Prediction of Creatinine-Drug Interactions
    Scotcher, Daniel
    Arya, Vikram
    Yang Xinning
    Zhao Ping
    Zhang Lei
    Huang Shiew-Mei
    Rostami-Hodjegan, Amin
    Galetin, Aleksandra
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2020, 9 (05): : 282 - 293
  • [2] MECHANISTIC PBPK MODELING OF CREATININE-DRUG INTERACTIONS IN CHRONIC KIDNEY DISEASE POPULATION.
    Takita, H.
    Scotcher, D.
    Chinnadurai, R.
    Kalra, P.
    Galetin, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S59 - S60
  • [3] MECHANISTIC PBPK MODELING OF CREATININE-DRUG INTERACTIONS IN CHRONIC KIDNEY DISEASE POPULATION.
    Takita, H.
    Scotcher, D.
    Chinnadurai, R.
    Kalra, P.
    Galetin, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S85 - S85
  • [4] Physiologically-Based Pharmacokinetic Modelling of Creatinine-Drug Interactions in the Chronic Kidney Disease Population
    Takita, Hiroyuki
    Scotcher, Daniel
    Chinnadurai, Rajkumar
    Kalra, Philip A.
    Galetin, Aleksandra
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2020, 9 (12): : 695 - 706
  • [5] Inhibitory effects of vandetanib on creatinine transport via renal organic cation transporter OCT2
    Tanihara, Yuko
    Masuda, Satohiro
    Inui, Ken-ichi
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 158
  • [6] MECHANISTIC MODELS FOR COPROPORPHYRIN I AND CREATININE AS ENDOGENOUS BIOMARKERS FOR TRANSPORTER DRUG-DRUG INTERACTIONS
    Galetin, Aleksandra
    [J]. DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : S13 - S13
  • [7] A NOVEL OCT2/OCT3/MATE1 TRIPLE EXPRESSION MODEL FOR STUDYING ACTIVE CREATININE EXCRETION IN THE KIDNEY
    Huang, Yong
    Kosaka, Alan
    Huang, Jane
    Warren, Mark S.
    Zhang, John
    [J]. DRUG METABOLISM REVIEWS, 2012, 44 : 142 - 142
  • [8] Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium
    Dumitras, Swati
    Sechaud, Romain
    Drollmann, Anton
    Pal, Parasar
    Vaidyanathan, Sivakumar
    Camenisch, Gian
    Kaiser, Guenther
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2013, 51 (10) : 771 - 779
  • [9] IN VITRO-IN VIVO CORRELATION (IVIVC) OF DRUG INDUCED INHIBITION OF CREATININE TUBULAR SECRETION USING MDCK CELLS EXPRESSING OCT2/OAT2/OCT3/MATE1/MATE2K TRANSPORTERS.
    Zhang, X.
    Jiang, W.
    Li, C.
    Huang, J.
    Huang, Y.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S60 - S60
  • [10] Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine
    Mueller, Fabian
    Koenig, Joerg
    Hoier, Eva
    Mandery, Kathrin
    Fromm, Martin F.
    [J]. BIOCHEMICAL PHARMACOLOGY, 2013, 86 (06) : 808 - 815
12